Baidu
map

CONH:活化去乙酰化酶或为肾病治疗新策略

2014-04-21 王姗(译) 医学论坛网

来自日本的Munehiro Kitada等人通过回顾研究发现,去乙酰化酶SIRT1和SIRT3的活化可能为肾脏疾病提供新的治疗策略,但常染色体显性遗传多囊肾病(ADPKD)除外。该论文发表于近期的《肾脏病学和高血压的现代观点》杂志. 越来越多的证据显示了去乙酰化酶在年龄相关疾病中的益处,如糖尿病、神经元疾病、心血管疾病及肾脏病。去乙酰化酶为NAD+依赖的去乙酰化酶包括SIRT1和SIR

来自日本的Munehiro Kitada等人通过回顾研究发现,去乙酰化酶SIRT1和SIRT3的活化可能为肾脏疾病提供新的治疗策略,但常染色体显性遗传多囊肾病(ADPKD)除外。该论文发表于近期的《肾脏病学和高血压的现代观点》杂志.

越来越多的证据显示了去乙酰化酶在年龄相关疾病中的益处,如糖尿病、神经元疾病、心血管疾病及肾脏病。去乙酰化酶为NAD+依赖的去乙酰化酶包括SIRT1和SIRT3。

目前最新研究成果显示SIRT1可使多种靶分子去乙酰化,如转录因子和蛋白,并可通过其降低纤维化、抗凋亡、抗炎作用以及诱导肾脏细胞自体吞噬而表现出肾脏保护作用。SIRT1还可能通过钠转运和降低血管紧张素Ⅱ的反应性参与到血压调节过程中。然而,SIRT1可能在ADPKD中参与促进肾脏上皮细胞的囊肿形成。SIRT3可通过其抗氧化及抗炎作用保护肾小管细胞免于棕榈酸酯诱发的脂毒性。

原始出处

Kitada M1, Kume S, Koya D.Role of sirtuins in kidney disease.Curr Opin Nephrol Hypertens. 2014 Jan;23(1):75-9.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=34397, encodeId=b7c23439e81, content=最近发现很多靶点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=259, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060507, encodeId=7c63206050eb4, content=<a href='/topic/show?id=d4183e22569' target=_blank style='color:#2F92EE;'>#去乙酰化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37225, encryptionId=d4183e22569, topicName=去乙酰化酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Jul 05 14:38:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748776, encodeId=6fb21e48776af, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Mon Aug 18 11:38:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478344, encodeId=4dd414e83442a, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Apr 23 01:38:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
    2015-08-04 sundong

    最近发现很多靶点啊

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=34397, encodeId=b7c23439e81, content=最近发现很多靶点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=259, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060507, encodeId=7c63206050eb4, content=<a href='/topic/show?id=d4183e22569' target=_blank style='color:#2F92EE;'>#去乙酰化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37225, encryptionId=d4183e22569, topicName=去乙酰化酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Jul 05 14:38:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748776, encodeId=6fb21e48776af, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Mon Aug 18 11:38:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478344, encodeId=4dd414e83442a, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Apr 23 01:38:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=34397, encodeId=b7c23439e81, content=最近发现很多靶点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=259, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060507, encodeId=7c63206050eb4, content=<a href='/topic/show?id=d4183e22569' target=_blank style='color:#2F92EE;'>#去乙酰化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37225, encryptionId=d4183e22569, topicName=去乙酰化酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Jul 05 14:38:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748776, encodeId=6fb21e48776af, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Mon Aug 18 11:38:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478344, encodeId=4dd414e83442a, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Apr 23 01:38:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=34397, encodeId=b7c23439e81, content=最近发现很多靶点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=259, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060507, encodeId=7c63206050eb4, content=<a href='/topic/show?id=d4183e22569' target=_blank style='color:#2F92EE;'>#去乙酰化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37225, encryptionId=d4183e22569, topicName=去乙酰化酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Jul 05 14:38:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748776, encodeId=6fb21e48776af, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Mon Aug 18 11:38:00 CST 2014, time=2014-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478344, encodeId=4dd414e83442a, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Wed Apr 23 01:38:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]

相关资讯

Org Lett:灵芝和九香虫可能防治慢性肾病

中科院昆明植物研究所研究员程永现指导博士生晏永明发现,著名中药灵芝和九香虫可治疗慢性肾病。研究成果日前发表于《有机化学通讯》。 据介绍,慢性肾脏病在国内外的发病率已高达10%以上。该病较为隐匿,缺乏治疗药物,易进一步导致肾衰,进而使患者依赖于血液透析和肾脏移植。由于慢性肾脏病发病机制复杂,因此科研人员认为从中草药中寻找新的防治药物是可能的。 赤芝是中国药典收载的灵芝的一种,自古

AJKD:高血压前期是发生终末期肾病的独立危险因素

2014年1月KidneyDis发表了南方医科大学南方医院心血管内科撰写的关于高血压前期与终末期肾病(ESRD)危险性的Meta分析。 研究对美国、日本、挪威、中国等多个国家的前瞻性队列研究进行Meta分析,最终纳人人群超过100万(其中25.6%的亚洲人群),采用95%,的ESRD相对风险(RRS)作为主要终点,并根据血压、年龄、性别、种族和研究特征进行亚组分析。 结果发现,校正了吸烟、血糖

Nutr Hosp :高蛋白饮食可能会增加肾病风险

高蛋白质饮食,如Dukan饮食,是目前流行的一种替代传统的卡路里节食。但西班牙Granada大学的科学家在老鼠实验中却发现,高蛋白饮食会增加患肾结石和其他肾脏疾病的风险。 Pierre博士的高蛋白饮食方法近几年颇为流行,由于报道说,这种饮食帮助了剑桥公爵夫人变得足够苗条,使得她穿上了美丽的婚纱,也帮助了珍妮弗。洛佩兹产后身材的恢复。 但是这种饮食方法却颇有争议,英国日常饮食协会公布了201

谌贻璞:对2型糖尿病患者中CKD的高患病率应予高度重视

近十余年,国内已发表了几篇有关2型糖尿病(T2DM)患者慢性肾脏病(CKD)患病率的流调报告。2002年,中华医学会糖尿病学分会发表了 全国住院糖尿病患者慢性并发症的调查报告,其中并发临床肾脏病(包括慢性肾功能不全及尿毒症)者占33.6%;2008年上海复旦大学发表了他们组织的上海市市区30岁以上T2DM患者的流调报告,CKD患病率高达63.9%;而2012年江苏省老年病研

Science:中美洲肾病的神秘面纱

物理学家Emmanuel Jarquin正在一个合作项目中研究一种令中美洲农业工人苦恼的神秘疾病——病因不明的慢性肾脏疾病(CKDu)。关于CKDu的第一次报道出现在2002年,它与糖尿病和高血压并没有已知的联系。关于CKDu的情况被粗略的卫生统计所掩盖,且很难将其与其他肾脏疾病进行区分。但它似乎开始在中美洲太平洋海岸炎热的低地上蔓延,人们对它的忧虑日益增加。去年10月,泛美卫生组织(PAHO

NEJM:糖尿病肾病新药甲基巴多索隆临床3期试验失败(BEACON试验)

糖尿病肾病仍然是临床治疗的难题,华盛顿大学医学院肾脏研究院的Himmelfarb博士等对糖尿病肾病的治疗现状和药物研究情况进行了评述,文章近期发表于The New England Journal of Medicine上。【原文下载】 肥胖加剧了糖尿病肾病的发生,目前糖尿病肾病已成为公共健康的一大挑战。发达和发展中国家,糖尿病肾病是慢性肾疾病的最常见病因,最终导致肾终

Baidu
map
Baidu
map
Baidu
map